Sartorius Stedim Biotech: Barclays upgrades stock

(CercleFinance.com) - On Wednesday, Barclays upgraded Sartorius Stedim Biotech shares from 'equal weight' to 'overweight', with a target price raised from E200 to E250.


The broker hails the emergence of a 'new world' for the pharmaceutical and biopharmaceutical manufacturing industry, of which Sartorius Stedim Biotech is one of the two leading specialists in Europe along with its parent company Sartorius.

According to the analyst's calculations, the sector is only one quarter away from returning to the normal trajectory it would have followed without the emergence of Covid.

Despite this, both Sartorius Stedim Biotech and Sartorius are trading at much lower valuation levels than their peers, the analyst points out.


Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.